Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 783 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioequivalence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib (LY2484595) in Healthy Participants

NCT01903434
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

NCT00864448
View directory record Official record
Conditions
Healthy
Interventions
Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg

NCT00647985
View directory record Official record
Conditions
Healthy
Interventions
Fexofenadine Tablets 180 mg, Allegra® Tablets 180 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

NCT04277624
View directory record Official record
Conditions
Healthy Volunteers
Interventions
fezolinetant - test formulation, fezolinetant - reference formulation
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women

NCT01535820
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay, Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg

NCT00650065
View directory record Official record
Conditions
Healthy
Interventions
Cetirizine HCl Tablets 10 mg, Zyrtec® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

NCT06609161
View directory record Official record
Conditions
Healthy
Interventions
Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

NCT01258530
View directory record Official record
Conditions
Influenza, Human
Interventions
over-encapsulated oseltamivir, oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions

NCT00835588
View directory record Official record
Conditions
Healthy
Interventions
Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
2
States / cities
Saint Charles, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System With Askina Derm Overlay

NCT00647686
View directory record Official record
Conditions
Healthy
Interventions
Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay, Fentanyl Transdermal System 25 mcg/h
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Limited Food Effect Study of Gabapentin 800 mg Tablets

NCT00865631
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions

NCT01659931
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Singulair
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

NCT00472927
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin/MPA 0.45 mg/1.5 mg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

NCT01188031
View directory record Official record
Conditions
Healthy
Interventions
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2010 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

NCT00648154
View directory record Official record
Conditions
Healthy
Interventions
Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

NCT00835497
View directory record Official record
Conditions
Healthy
Interventions
5 mg/500 mg Glipizide Metformin Hydrochloride Tablets, 5 mg/500 mg METAGLIP™ Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

NCT00865761
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fasting Conditions

NCT01131923
View directory record Official record
Conditions
Healthy
Interventions
Amlodipine
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

NCT05722262
View directory record Official record
Conditions
Healthy
Interventions
K-001, K-877-ER, CSG452
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food BE Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage XR 500 mg

NCT00649948
View directory record Official record
Conditions
Healthy
Interventions
Metformin Hydrochloride ER Tablets 500 mg, Glucophage XR 500 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

NCT07261371
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C), Test formulation (Treatment D)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg

NCT00647621
View directory record Official record
Conditions
Healthy
Interventions
Extended Phenytoin Sodium Capsules 100 mg, Dilantin® Kapseals® 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

NCT00840216
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 22, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.

NCT01632449
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Test product, Reference product
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 22, 2026, 2:18 AM EDT